All Articles
By Wayne Kuznar
Sorafenib (Nexavar) in combination with transcatheter arterial chemoembolization (TACE) significantly improves progression-free survival (PFS), with no unexpected adverse results, compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), according to results from the phase 2 TACTICS clinical trial. Read More ›
Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis. Read More ›
By Wayne Kuznar
The addition of abiraterone acetate (Zytiga) to androgen-deprivation therapy (ADT) did not increase medical resource utilization in patients with metastatic castration-naïve prostate cancer who participated in the multinational LATITUDE clinical trial. Read More ›
Approximately 25% of women with gynecologic malignancies cannot afford the cost of their medical care, according to a study presented at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›
Participation in clinical trials may help to overcome health disparities in the treatment of advanced or recurrent ovarian cancer, and minority patients should be encouraged to participate, said Khilen B. Patel, MD, Obstetrics & Gynecology Resident, Medical College of Georgia, Augusta University, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›
By Phoebe Starr
Chimeric antigen receptor (CAR) T-cell therapy has had excellent results in late-stage leukemia and varying degrees of success in some other hematologic cancers, but thus far, solid tumors have not responded to this therapy. Read More ›
Metastatic estrogen receptor (ER)-positive breast cancer responds well to anti-ER therapies, but eventually resistance occurs and the drugs fail to work. A new study presented at the 2018 AACR meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›
By Phoebe Starr
The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and a high tumor mutational burden (TMB). This finding was unrelated to levels of PD-L1 expression, said Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York City. Read More ›